VidavoATH:VIDAVO 83 Return-on-Tangible-Equity is 277.59% as of Dec. 2025, which is 2592% above its 10-year median of 10.31. GuruFocus rates ATH:VIDAVO with a GF Score™ of 83/100 and a GF Value™ of €8.49 (Fairly Valued). The stock has 6 warning signs investors should review. Among 579 Healthcare Providers & Services companies, Vidavo ranks better than 86.36% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vidavo's annualized net income for the quarter that ended in Dec. 2025 was €1.85 Mil. Vidavo's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €0.67 Mil. Therefore, Vidavo's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 277.59%.
The historical rank and industry rank for Vidavo's Return-on-Tangible-Equity or its related term are showing as below:
ATH:VIDAVO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -45.3 Med: 10.31 Max: 108.01
Current: 108.01
During the past 13 years, Vidavo's highest Return-on-Tangible-Equity was 108.01%. The lowest was -45.30%. And the median was 10.31%.
ATH:VIDAVO's Return-on-Tangible-Equity is ranked better than 86.36% of 579
companies
in the Healthcare Providers & Services industry
Industry Median: 10.21
vs ATH:VIDAVO: 108.01
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Vidavo Return-on-Tangible-Equity Related Terms
Vidavo Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Vidavo's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATH:VIDAVO vs VEEV, BTSG, TEM: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, Vidavo's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vidavo Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Vidavo's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Vidavo's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 277.59% mean?
Vidavo (ATH:VIDAVO) has a Return-on-Tangible-Equity of 277.59% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vidavo and its competitors. This is 2592% above median its historical median of 10.31. According to the industry distribution chart, Vidavo ranks #79 out of 579 companies in the Healthcare Providers & Services industry, placing it in the top 13.6%.
Is Vidavo's Return-on-Tangible-Equity too high?
Vidavo's current Return-on-Tangible-Equity of 277.59% is 2592% above median its 10-year median of 10.31. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.21. Vidavo's value of 277.59% is 2618.8% above this industry median. Based on the distribution chart, Vidavo ranks #79 out of 579 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Vidavo has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vidavo's Return-on-Tangible-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Vidavo ranks #79 out of 579 companies for Return-on-Tangible-Equity. This places Vidavo in the top 14% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.21. Vidavo's value of 277.59% is 2618.8% above this benchmark. While the company's 10-year median is 10.31 vs. the industry median of 10.21, Vidavo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.21, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vidavo's current Return-on-Tangible-Equity of 277.59% is 2618.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vidavo and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vidavo's current Return-on-Tangible-Equity is 277.59%, which is 2592% above median its own 10-year median of 10.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vidavo stock overvalued right now?
Based on GuruFocus' analysis, Vidavo (ATH:VIDAVO) is currently considered Fairly Valued. The stock's GF Value™ is €8.49, compared to a current price of €8.60 — trading 1.3% above its estimated fair value. The current Return-on-Tangible-Equity is 277.59%, which is 2592% above median its 10-year median of 10.31 and 2618.8% above the Healthcare Providers & Services industry median of 10.21. Vidavo's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Vidavo (ATH:VIDAVO), the current Return-on-Tangible-Equity is 277.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vidavo (ATH:VIDAVO) Overvalued in 2026?
Based on GuruFocus' analysis, Vidavo stock appears to be overvalued.
The current stock price of €8.60 is trading 1.3% above its estimated GF Value™ of €8.49.
GuruFocus considers Vidavo to be Fairly Valued.
Key valuation signals for ATH:VIDAVO:
Return-on-Tangible-Equity: 277.59% (2592% above median its 10-year median of 10.31)
GF Value™: €8.49 vs. price of €8.60 (1.3% above fair value)
Industry Position: 2618.8% above the Healthcare Providers & Services median (#79 of 579)
No single metric tells the full story. See the ATH:VIDAVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vidavo SA develops mobile applications that help citizens on-the-move and medical professionals manage health and wellness. The company serves health and social care providers, policymakers, insurance companies, ICT firms seeking differentiation, patients, telecom operators, and other health-related stakeholders. Its solutions include vida24, vidatrack, and vidahome.
83GF Score
Get the complete analysis for ATH:VIDAVO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATH:VIDAVO has been successfully added to your 
